Related Experiment Video
Updated: Jun 21, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
Published on: June 24, 2025
Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks
Ali Mirza Onder1, Jayanthi Chandar, Anthony Billings
1West Virginia University, WVU/HSC, Morgantown, 26506-9214, USA. alim_md@hotmail.com
Insights
Tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) significantly reduced catheter-related bacteremia in high-risk children undergoing hemodialysis. Prophylactic TPA/tobra ABLs also improved catheter survival rates in this vulnerable patient group.
Area of Science:
- Nephrology
- Infectious Diseases
- Pediatrics
Background:
- Catheter-related bacteremia (CRB) is a significant complication in children on long-term hemodialysis.
- High-risk pediatric patients often experience poorer catheter survival due to infections.
Purpose of the Study:
- To evaluate the efficacy of tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) for CRB prophylaxis.
- To assess the impact of TPA/tobra ABLs on catheter survival in high-risk pediatric hemodialysis patients.
Main Methods:
- Retrospective study analyzing 16,412 catheter days in 43 children.
- Implementation of TPA/tobra ABL prophylaxis in a high-risk group across different frequencies (every session vs. weekly).
- Comparison of CRB incidence and catheter survival between high-risk and average-risk groups, and across different prophylaxis regimens.
Main Results:
- A significant decrease in CRB incidence was observed with TPA/tobra ABL prophylaxis in the high-risk group (P = 0.0201).
- A trend towards reduced CRB was noted when prophylaxis was applied after every hemodialysis session compared to weekly (P = 0.0947).
- TPA/tobra ABL prophylaxis significantly improved both overall and infection-free catheter survival in high-risk patients, normalizing outcomes compared to the average-risk group.
Conclusions:
- TPA/tobra ABLs are effective in reducing CRB rates in high-risk pediatric hemodialysis patients.
- Prophylactic use of TPA/tobra ABLs can prolong both overall and infection-free catheter survival in this population.
Abstract:
This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

